Ethylene Oxide EtO Cases in 2026: Intake and Marketing Strategy for Plaintiff Firms

Ethylene Oxide EtO: The Business Case for Plaintiff Firms in 2024

Ethylene oxide mass tort marketing has become essential for plaintiff firms seeking to compete in a litigation space where case acquisition costs and settlement valuations are converging toward equilibrium. The Sterigenics verdicts and subsequent multi-hundred-million-dollar settlements established liability precedent that transformed EtO exposure into a genuine volume play, but competitive saturation is accelerating case acquisition costs across major markets. For firms evaluating deployment of capital into this tort, the critical variable is no longer case availability—it's identifying which geographic and exposure channels still offer acceptable economics before market consolidation concludes.

I've spent 15+ years managing mass tort advertising campaigns across 100+ torts for 600+ plaintiff law firms. We've deployed over $250M in Facebook ad spend alone. Ethylene oxide mass tort marketing is different from many legacy torts because the litigation infrastructure is young, the settlement benchmarks are clear, and the geography is concentrated. But that concentration is also the trap: firms that move fast capture the high-density clusters (Willowbrook IL, Waukegan IL, Covington GA). Firms that hesitate fight for scraps in secondary markets or face CPL inflation that erodes case economics. This post breaks down the real numbers—litigation landscape, claimant pool size, advertising costs, intake qualification, and timing—so you can make an informed decision about whether EtO fits your firm's acquisition strategy.

The Litigation Landscape: MDL Coordination, Bellwethers, and Case Value Timing

First, understand the structural reality. Ethylene oxide cases are NOT formally consolidated into a traditional MDL. Instead, cases are coordinated in N.D. Illinois under various judges, with Sterigenics/Willowbrook as the anchor. This matters because it means:

• No consolidated stay. Cases are not frozen pending MDL resolution. Discovery and motion practice continue in parallel across jurisdictions. This accelerates some cases but creates docket complexity.
• Multiple defendants, multiple exposure sites. Sterigenics operated multiple facilities. Medline Industries (Waukegan IL), Becton Dickinson (Covington GA, Atlanta GA), and STERIS (Laredo TX) each have separate litigation tracks. A claimant near one facility may have different defendants than a claimant near another.
• Bellwether trials are ongoing. The Kamuda verdict in 2022 ($363M) was not an isolated fluke—it was a beta test. More trials have followed. This means case values are being *validated* in real time, not predicted on spreadsheets.
• Settlement benchmarks exist. The Sterigenics $408M settlement fund established per-case payouts tied to injury type (breast cancer, NHL) and exposure duration. This gives firms a floor for case valuation and allows serious underwriting.

For your firm: this is a *live* litigation environment, not a pre-MDL holding pattern. Cases that meet causation thresholds can move toward trial or settlement within 18–36 months. This compresses the time window for case acquisition. If you acquire cases today, you're funding intake, retention, and expert work with a realistic path to settlement or judgment visible on the horizon. That's rare in mass tort. It also means defendants are actively settling to avoid bellwether losses. Settlement value inflation is real.

The Claimant Pool and Saturation: Who's Left, and Where?

Ethylene oxide mass tort marketing requires precision on addressable demand. Here's the geography:

• Willowbrook, IL (Sterigenics): Largely resolved via $408M settlement. This market is saturated. Remaining cases are either outliers (exceptional damages) or spillover from competing firms' intake failures. CPL here runs $400–$800 because you're fighting established players on ground they've already worked.
• Waukegan, IL (Medline Industries): This is the active hunting ground. Medline operates a massive sterilization facility in a residential area. Estimated 80,000–120,000 people lived within the primary exposure zone (1–3 miles) during the relevant exposure window (2000–2022). Current litigation includes 400+ filed cases. Competing firms are present but not dominant. This is *still* open.
• Covington, GA & Atlanta, GA (Becton Dickinson): BD operates multiple facilities in Georgia. Exposure footprint is large. Litigation is accelerating. Case volume here is estimated at 200–500 viable claimants. This market is newer; saturation is lower than Illinois. CPL is competitive.
• Laredo, TX (STERIS): Emerging. STERIS operates a sterilization facility in a lower-income border community. Exposure numbers are high, legal sophistication among claimants is lower, and competing firm presence is minimal. This is a frontier market with higher conversion rates but longer case-to-settlement timelines.

The addressable pool across all EtO sterilization facilities is estimated at 1,500–3,000 viable claimants. We're not talking about 50,000-claimant talc or 100,000-claimant opioid litigation. EtO is smaller but more concentrated, which means:

• Geographic targeting is hyper-effective. You can laser-focus ad spend on 1–3 mile radii around known facilities.
• Market saturation happens faster. Once the top 5–10 firms in a geography have hit their capacity, CPL jumps and conversion falls.
• First-mover advantage is real. Early entrants in Waukegan and Georgia captured cases at $800–$1,200 CPL two years ago. Current CPL in Waukegan is $1,800–$2,400, depending on channel and creative.

Bottom line: if you're entering EtO now, Waukegan and Georgia are still viable. Willowbrook is closed. Laredo is early-stage and lower-saturation but requires patience on timeline. Saturation is rising, and CPL inflation is 15–20% year-over-year in active markets.

Ethylene Oxide Mass Tort Marketing: Channels, Costs, and Creative Strategy

Now the mechanics. Ethylene oxide mass tort marketing works across multiple channels, but the economics vary dramatically by channel and by market maturity.

Facebook / Instagram Ads (50–60% of volume): This is the dominant channel for EtO. Why? The claimant pool is local, mid-40s to 70+, and spends time on Facebook. Geo-targeting to 2-mile radii around known facilities works exceptionally well. Typical performance:

• CPL: $800–$2,400 depending on market and creative freshness
• Cost per signed case: $6,000–$15,000 (this assumes 40–55% of leads qualify and 30–50% of qualified leads sign)
• Creative that works: "Did you live near [Facility Name]? Cancer diagnosis linked to sterilization emissions" with local news clips, settlement/verdict imagery, and named plaintiff testimonials. Avoid victim language; lead with verdict/settlement facts.

Google Local Services Ads (20–25% of volume): Google LSA for "mesothelioma lawyer near me" and related search terms. Works less effectively than Facebook for EtO because EtO claimants are less likely to be actively searching for a lawyer at 2 AM. But a fraction of your audience is actively googling; LSA captures them. Typical CPL: $1,200–$3,200. High conversion rate (45–65% lead quality) but lower volume overall.

Radio and Local Broadcast (10–15% of volume): In concentrated markets like Waukegan, local radio spots and cable TV spots reach older demographics who don't use Facebook. Effective for volume in secondary markets and rural areas (Laredo). CPL is higher ($2,400–$4,000) but mix matters if your target skews 65+.

Direct Mail (5–10% of volume): Targeted mail to homes in 1–3 mile radius of known facilities. Works slowly and requires 3–4 mail drops to convert. CPL is $3,000–$6,000 but conversion is consistent. Useful for secondary pass over a geographic market or for older demographics in rural areas.

Across channels, realistic cost-per-signed-case for ethylene oxide mass tort marketing in active markets is $8,000–$12,000. In saturated markets (Willowbrook), bump that to $15,000–$25,000. In frontier markets (Laredo), you may hit $6,000–$10,000 CPL but with 2–3 month longer case acquisition cycles.

Creative angles that *convert* in EtO campaigns:

• Named verdict/settlement facts ($363M, $408M) from real cases
• Facility imagery and emission data (EPA reports, news coverage)
• Causation simple: "EtO is a known carcinogen. If you lived near a sterilization facility and developed cancer, you may have a claim."
• Named plaintiffs or testimonial clips from existing clients (not "victims," but *case plaintiffs*)
• Geographic specificity: "Waukegan IL residents," "Covington GA residents," never generic

Intake Qualification and Case Retention: The Real Filter

Lead volume is meaningless if qualification rates are low. EtO intake is straightforward but has real gating factors:

Primary qualification filters:

• Geography: Did the claimant live or work within 1–3 miles of a known EtO sterilization facility for 12+ consecutive months during the relevant exposure window (typically 2005–2022, depending on facility)?
• Diagnosis: Breast cancer, non-Hodgkin lymphoma, or other EtO-linked cancers. Other diagnoses (lung cancer, ovarian) require additional epidemiologic support and are harder sells. Qualification rates for NHL and breast cancer: 60–70%. For other cancers: 20–30%.
• Causation packaging: Residential proximity is the causation link. A claimant who lived 0.5 miles from the facility for 15 years is a slam dunk. A claimant who lived 2.5 miles away for 3 years is marginal. Your intake team needs to screen for proximity (pull census data, use address mapping tools) and exposure duration before signing.
• Damages: EtO cases are valued primarily on cancer diagnosis (stage matters) and exposure duration/proximity. Economic damages (lost wages, medical costs) are secondary. A claimant with stage III breast cancer who lived 0.5 miles from the facility for 10+ years may be worth $200K–$500K+ in settlement range. A claimant with early-stage cancer at 2+ miles from the facility may be worth $40K–$80K. Your intake needs to capture this data upfront so you can underwrite portfolio economics.

Real-world qualification rates in mature markets: 35–50% of leads meet geographic/diagnostic thresholds. Of those, 40–60% sign retainers. This means your true conversion from lead to signed case is 14–30%, depending on intake quality and messaging. Better intake processes (faster callbacks, better geographic verification, clearer case-value discussion) push conversion toward 25–30%. Weaker intake (slow follow-up, unclear value proposition, poor data capture) drops it to 14–18%.

Case retention (signed case stays with your firm and doesn't go to a competitor) is 85–95% for EtO. Why? The litigation ecosystem is still forming, and claimants don't have years of experience shopping their cases between firms. Early-signed cases are sticky. This changes as markets saturate, but for now, retention is not a major leak.

How MTAA Structures Ethylene Oxide Mass Tort Marketing Campaigns

At MTAA, we've run $15M+ in EtO campaigns for 40+ firms across all four major geographic clusters. Here's how we approach it:

Campaign architecture: We start with a geographic audit—which facilities are most active in litigation, which markets are least saturated, which claimant pools are largest and least tapped. For a given firm, we recommend 2–3 geographic targets, not one. Diversification reduces saturation risk. Then we build channel mix: 50–60% Facebook/Instagram, 20–25% Google LSA, 15–20% radio/local digital, 5–10% direct mail or online search. Creative is refreshed every 4–6 weeks to combat ad fatigue.

Intake integration: We don't just drive leads to a landing page. We work with your intake team to design the intake flow, the questions that matter (geography, diagnosis, timeline), and the qualification criteria. We measure not just lead volume but qualified lead rate and signed-case rate. We adjust channel mix and creative based on which channels produce the highest-quality leads (not just the cheapest).

Pricing: MTAA operates on transparent cost-plus: we charge your actual ad spend plus a 15% management fee. If you're running a $50K/month Facebook campaign, you pay $50K + $7,500 management. No markup on media, no black-box pricing. This aligns us with your economics—we care about cost per signed case and case quality, not just CPL or lead volume.

Timeline expectations: A typical EtO campaign ramps over 6–8 weeks and runs 6–12 months minimum. Most firms see peak case velocity at months 3–6, then plateau. Geographic saturation is real. We recommend rotating into new geographies at month 8–10 if volumes are declining.

Closing: Is Ethylene Oxide Mass Tort Marketing Right for Your Firm?

Ethylene oxide mass tort marketing is viable, but only if you move now. The litigation landscape is proven (verdicts and settlements are real), the claimant pools are defined (not speculative), and the case economics are sound. A claimant portfolio of 50–100 EtO cases, with a mix of breast cancer and NHL diagnoses and reasonable proximity to facilities, can generate $5M–$15M in settlement value over 24–36 months.

But saturation is real. Willowbrook is closed. Waukegan is competitive. Georgia is open but tightening. Laredo is a frontier but requires patience. If you're considering EtO, the decision point is now: do you have the capital to invest in acquisition, the intake infrastructure to handle qualification at scale, and the portfolio appetite for cancer cases? If yes, ethylene oxide mass tort marketing can be a profitable part of your firm's growth strategy. If you're hesitant or under-resourced, wait 12–18 months and recalibrate—the opportunity won't disappear, but the CPL will double.

MTAA has the expertise, the data, and the execution capability to run this for you. We've managed 600+ firms across 100+ torts and deployed $250M+ in media spend. We know what works in ethylene oxide mass tort marketing, what the real costs are, and how to build sustainable case acquisition in maturing litigation environments. If you want to talk through whether EtO fits your strategy, let's connect.